[144] Sionna Therapeutics, Inc. SEC Filing
Sionna Therapeutics (SION) filing of a Form 144 notifies the proposed sale of 34,500 shares of common stock through Morgan Stanley Smith Barney LLC on 08/19/2025. The shares have an aggregate market value of $737,955.00 and the company reports 44,139,823 shares outstanding. The securities were acquired on 09/20/2022 through previously exercised stock options from the issuer and were paid for in cash. The filer reports "Nothing to Report" for securities sold during the past three months. The notice includes the filers representation that they do not possess undisclosed material adverse information.
Sionna Therapeutics (SION) ha notificato tramite il deposito di un Form 144 la proposta di vendita di 34.500 azioni ordinarie tramite Morgan Stanley Smith Barney LLC in data 19/08/2025. Le azioni hanno un valore di mercato complessivo di $737.955,00 e la società comunica di avere 44.139.823 azioni in circolazione. I titoli sono stati acquisiti il 20/09/2022 mediante opzioni su azioni esercitate in precedenza dall'emittente e sono stati pagati in contanti. Il dichiarante riporta "Nothing to Report" per le vendite di titoli effettuate negli ultimi tre mesi. Nell’avviso il dichiarante dichiara inoltre di non possedere informazioni riservate materialmente negative non divulgate.
Sionna Therapeutics (SION) ha presentado un Form 144 que notifica la propuesta de venta de 34.500 acciones ordinarias a través de Morgan Stanley Smith Barney LLC el 19/08/2025. Las acciones tienen un valor de mercado agregado de $737.955,00 y la compañía informa que hay 44.139.823 acciones en circulación. Los valores fueron adquiridos el 20/09/2022 mediante opciones sobre acciones previamente ejercidas del emisor y fueron pagados en efectivo. El declarante informa "Nothing to Report" respecto a valores vendidos durante los últimos tres meses. El aviso incluye la declaración del declarante de que no posee información adversa material no divulgada.
Sionna Therapeutics (SION)가 Form 144를 제출하여 2025-08-19에 Morgan Stanley Smith Barney LLC를 통해 34,500주의 보통주를 매각할 예정임을 통지했습니다. 해당 주식들의 총 시가총액은 $737,955.00이고 회사는 44,139,823주의 발행 주식을 보고했습니다. 이 증권은 2022-09-20에 발행사로부터 이전에 행사된 주식매수옵션을 통해 취득되었으며 현금으로 지급되었습니다. 신고인은 지난 3개월 동안 매도한 증권에 대해 "Nothing to Report"라고 보고했습니다. 통지서에는 신고인이 미공개 중요 불리 정보가 없음을 진술한 내용도 포함되어 있습니다.
Sionna Therapeutics (SION) a déposé un Form 144 notifiant la vente prévue de 34 500 actions ordinaires via Morgan Stanley Smith Barney LLC le 19/08/2025. Les actions ont une valeur de marché totale de $737 955,00 et la société déclare détenir 44 139 823 actions en circulation. Les titres ont été acquis le 20/09/2022 par l'exercice antérieur d'options sur actions émises par l'émetteur et ont été payés en espèces. Le déclarant indique "Nothing to Report" pour les titres vendus au cours des trois derniers mois. L'avis comprend la représentation du déclarant selon laquelle il ne détient pas d'informations défavorables importantes non divulguées.
Sionna Therapeutics (SION) hat durch die Einreichung eines Form 144 den geplanten Verkauf von 34.500 Stammaktien über Morgan Stanley Smith Barney LLC am 19.08.2025 angezeigt. Die Aktien haben einen gesamten Marktwert von $737.955,00, und das Unternehmen meldet 44.139.823 ausstehende Aktien. Die Wertpapiere wurden am 20.09.2022 durch zuvor ausgeübte Aktienoptionen des Emittenten erworben und mit Bargeld bezahlt. Der Melder gibt für in den letzten drei Monaten verkaufte Wertpapiere "Nothing to Report" an. Die Mitteilung enthält außerdem die Erklärung des Melders, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen vorliegen.
- Regulatory compliance: The filer provided required Rule 144 disclosure details, including broker, share count, and acquisition history.
- Transparency: Acquisition date (09/20/2022) and payment method (cash) are disclosed, aiding market clarity.
- Insider sale planned: The proposed sale of 34,500 shares by an insider may be perceived negatively by some investors.
Insights
TL;DR: Routine insider notice of proposed sale; transparent reporting but not materially transformative.
The Form 144 documents a planned sale of 34,500 common shares via Morgan Stanley Smith Barney LLC with an aggregate market value of $737,955. The shares were acquired by previously exercised options on 09/20/2022 and paid in cash. The filing states no sales in the past three months. This is a standard regulatory disclosure that enables market transparency about an insider-affiliated sale. The filing itself contains no earnings, financing, or covenant changes and does not disclose any undisclosed adverse information per the signers representation.
TL;DR: Proper compliance with Rule 144 reporting requirements; procedural rather than material news.
The notice provides required details: broker name and address, number of shares, acquisition date and method (previously exercised stock options), and payment nature (cash). It confirms no related sales in the prior three months and includes the standard signature representation about material information. From a governance perspective, the filing demonstrates adherence to disclosure rules but does not, by itself, indicate governance changes or material corporate events.
Sionna Therapeutics (SION) ha notificato tramite il deposito di un Form 144 la proposta di vendita di 34.500 azioni ordinarie tramite Morgan Stanley Smith Barney LLC in data 19/08/2025. Le azioni hanno un valore di mercato complessivo di $737.955,00 e la società comunica di avere 44.139.823 azioni in circolazione. I titoli sono stati acquisiti il 20/09/2022 mediante opzioni su azioni esercitate in precedenza dall'emittente e sono stati pagati in contanti. Il dichiarante riporta "Nothing to Report" per le vendite di titoli effettuate negli ultimi tre mesi. Nell’avviso il dichiarante dichiara inoltre di non possedere informazioni riservate materialmente negative non divulgate.
Sionna Therapeutics (SION) ha presentado un Form 144 que notifica la propuesta de venta de 34.500 acciones ordinarias a través de Morgan Stanley Smith Barney LLC el 19/08/2025. Las acciones tienen un valor de mercado agregado de $737.955,00 y la compañía informa que hay 44.139.823 acciones en circulación. Los valores fueron adquiridos el 20/09/2022 mediante opciones sobre acciones previamente ejercidas del emisor y fueron pagados en efectivo. El declarante informa "Nothing to Report" respecto a valores vendidos durante los últimos tres meses. El aviso incluye la declaración del declarante de que no posee información adversa material no divulgada.
Sionna Therapeutics (SION)가 Form 144를 제출하여 2025-08-19에 Morgan Stanley Smith Barney LLC를 통해 34,500주의 보통주를 매각할 예정임을 통지했습니다. 해당 주식들의 총 시가총액은 $737,955.00이고 회사는 44,139,823주의 발행 주식을 보고했습니다. 이 증권은 2022-09-20에 발행사로부터 이전에 행사된 주식매수옵션을 통해 취득되었으며 현금으로 지급되었습니다. 신고인은 지난 3개월 동안 매도한 증권에 대해 "Nothing to Report"라고 보고했습니다. 통지서에는 신고인이 미공개 중요 불리 정보가 없음을 진술한 내용도 포함되어 있습니다.
Sionna Therapeutics (SION) a déposé un Form 144 notifiant la vente prévue de 34 500 actions ordinaires via Morgan Stanley Smith Barney LLC le 19/08/2025. Les actions ont une valeur de marché totale de $737 955,00 et la société déclare détenir 44 139 823 actions en circulation. Les titres ont été acquis le 20/09/2022 par l'exercice antérieur d'options sur actions émises par l'émetteur et ont été payés en espèces. Le déclarant indique "Nothing to Report" pour les titres vendus au cours des trois derniers mois. L'avis comprend la représentation du déclarant selon laquelle il ne détient pas d'informations défavorables importantes non divulguées.
Sionna Therapeutics (SION) hat durch die Einreichung eines Form 144 den geplanten Verkauf von 34.500 Stammaktien über Morgan Stanley Smith Barney LLC am 19.08.2025 angezeigt. Die Aktien haben einen gesamten Marktwert von $737.955,00, und das Unternehmen meldet 44.139.823 ausstehende Aktien. Die Wertpapiere wurden am 20.09.2022 durch zuvor ausgeübte Aktienoptionen des Emittenten erworben und mit Bargeld bezahlt. Der Melder gibt für in den letzten drei Monaten verkaufte Wertpapiere "Nothing to Report" an. Die Mitteilung enthält außerdem die Erklärung des Melders, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen vorliegen.